Kim Borah, Lee Sang-Hyuk, Yang Yen Kuang, Park Jong-Il, Chung Young-Chul
Department of Psychiatry, CHA Bundang Medical Center, CHA University, 59 Yatap-ro, Bundang-gu, Seongnam-si 463-712, Gyeonggi-do, Republic of Korea.
Schizophr Res Treatment. 2012;2012:560836. doi: 10.1155/2012/560836. Epub 2012 Aug 14.
Clinical and psychosocial deterioration associated with schizophrenia occurs within the first few years following the onset of the illness. Therefore, to improve the long-term prognosis, it is important to provide schizophrenia patients with intensive treatment following their first episode. Relapse is highly associated with partial medication adherence or nonadherence in patients with first-episode schizophrenia. Recent studies suggest that long-acting injectable (LAI) antipsychotics compared with oral antipsychotics are more effective for medication adherence and relapse prevention. Moreover, some clinical guidelines for the treatment of schizophrenia suggested that LAI antipsychotics should be considered when patients are nonadherent "at any stage." Decreased compliance is a common cause of relapse during the initial stages of the disease. Therefore, LAI antipsychotics should be highly considered when treating patients with first-episode schizophrenia. In the present paper, clinical trial data and current guidelines on the use of LAI antipsychotics for first-episode schizophrenia are discussed as well as the pros and cons of this treatment option.
与精神分裂症相关的临床和社会心理恶化发生在疾病发作后的头几年内。因此，为改善长期预后，在首发精神分裂症患者首次发作后提供强化治疗很重要。复发与首发精神分裂症患者部分服药依从性或不依从性高度相关。最近的研究表明，与口服抗精神病药物相比，长效注射用（LAI）抗精神病药物在药物依从性和预防复发方面更有效。此外，一些精神分裂症治疗临床指南建议，当患者“在任何阶段”不依从时，应考虑使用LAI抗精神病药物。依从性降低是疾病初始阶段复发的常见原因。因此，在治疗首发精神分裂症患者时应高度考虑使用LAI抗精神病药物。在本文中，将讨论关于使用LAI抗精神病药物治疗首发精神分裂症的临床试验数据和当前指南，以及这种治疗选择的利弊。
